Austin Health
Austin Health
Melbourne, Victoria, Australia16 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, nervous system disorder, visual epilepsy | Recruiting | Phase 3 | 2026-10-08 | NCT05716100 | |
| Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART) | Blood-Borne Infections, Body Weight, Body Weight Changes, Genital Diseases, HIV infectious disease, Infections, Pathological Conditions, Signs and Symptoms, RNA Virus Infections, Signs and Symptoms, Urogenital Diseases, Weight Gain, immune system disorder, inborn error of immunity, infectious disease, lentivirus infection, sexually transmitted disease, uterine carcinosarcoma, viral infectious disease, viral sexually transmitted disease | Active, not recruiting | Phase 3 | 2026-07-22 | NCT06317051 | |
| Magnetic Resonance Imaging (MRI) Guided Stereotactic Adaptive Radiotherapy for Targeting Abdominal Cancer | Abdominal Cancer | Recruiting | Not applicable | 2026-05-08 | NCT06604533 | |
| Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Phase 2 | 2026-05-08 | NCT05694936 | |
| Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP) | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Recruiting | Phase 2 | 2026-05-06 | NCT06441747 | |
| Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD) | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Recruiting | Phase 3 | 2026-03-31 | NCT04939935 | |
| Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study | Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, Surgical Wound Infection, Wound Infection | Recruiting | Phase 4 | 2026-03-25 | NCT05447559 | |
| Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults | Bone Diseases, Metabolic, Critical Illness, Disease Attributes, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone disorder, metabolic disease, musculoskeletal system disorder, osteoporosis | Recruiting | Phase 2 | 2026-03-04 | NCT04608630 | |
| PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-03-03 | NCT05154162 | |
| Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2025-10-03 | NCT05840211 | |
| Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Active, not recruiting | Phase 2 | 2025-08-26 | NCT05796089 | |
| In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy | Metastatic Hormone Naive Prostate Cancer | Active, not recruiting | Phase 2 | 2025-07-11 | NCT04343885 | |
| A Randomised Clinical Trial of a Digital Self-management Package for People With Interstitial Lung Disease | Chronic Disease, Disease Attributes, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Recruiting | Not applicable | 2025-04-04 | NCT06122233 | |
| Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer | Breast Neoplasm Female | Active, not recruiting | Phase 1 | 2024-11-07 | NCT03900884 | |
| Electronic Capturing of Activities During REhabilitation for Upper Limb After Stroke | brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, nervous system disorder, stroke disorder, vascular disorder | Not yet recruiting | Not stated | 2024-07-30 | NCT06527261 | |
| The ElectRx Study - A Neurotechnology Approach to the Treatment of IBD | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Recruiting | Not applicable | 2023-02-08 | NCT05469607 |